Neurocrine Biosciences Advances CAH Treatment with Promising Results from CRENESSITY Studies

Neurocrine Biosciences, Inc. (NBIX) makes significant strides in treating congenital adrenal hyperplasia (CAH) with its investigational drug CRENESSITY (crinecerfont). Recent data from the Phase 3 CAHtalyst® Adult study reveals promising advancements over two years of treatment. Adult participants in the study demonstrate notable improvements in cardiometabolic health and quality of life. Impressively, 37% of those who were overweight or obese achieve a weight reduction exceeding 5%, while 43% of participants previously resistant to insulin no longer exhibit this condition after treatment. Furthermore, researchers observe decreases in glucocorticoid doses—often linked to obesity—indicating a substantial positive shift in health risks for this population. Assessment of bone health also uncovers encouraging trends in bone mineral density among participants. Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine, emphasizes that these results contribute to a redefined long-term approach in managing CAH, showcasing the transformative potential of CRENESSITY.

Key Findings from Pediatric Study

The Phase 3 CAHtalyst® Pediatric study reveals complementary findings, with two-year data presented at ENDO 2026 underlining the treatment’s efficacy in children and adolescents. Participants with initially advanced bone age exhibit slowed progression and increased predicted adult height after two years of therapy. Among the 41 children assessed, those with advanced bone age see a significant stabilization or improvement in bone age, while a select group sees enhancements in predicted adult height. Caregiver surveys indicate unanimous satisfaction with CRENESSITY, with strong recommendations for the treatment and optimism concerning future quality of life for these young patients. Dr. Keswani notes the critical impact these growth period treatment decisions can hold, reinforcing the necessity of effective hormone regulation to support normal growth trajectories.

Exploring CRENESSITY's Spectrum of Efficacy

Additional evidence of CRENESSITY’s versatility is showcased in a retrospective case series focusing on patients with CAH due to 11β-hydroxylase deficiency, a less common subtype. This pilot study includes 15 patients exhibiting substantial post-treatment hormone level reductions and significant glucocorticoid dose decreases, hinting at early therapeutic responses. Improvements in blood pressure are also reported, with adult patients on antihypertensives successfully reducing or discontinuing medication. This underscores Neurocrine's commitment to comprehensive care in the CAH community and highlights CRENESSITY’s promising role in managing this complex hormone imbalance, as noted by Dr. Keswani.

Overall, the progressive data emerging from Neurocrine Biosciences not only fortifies the understanding of CRENESSITY's benefits for both adult and pediatric CAH patients but also paves the path for more effective long-term management strategies, solidifying the company’s leading position in innovative treatments for hormonal disorders.